| Literature DB >> 29606126 |
Daichi Shikata1, Takahiro Nakagomi1, Rumi Higuchi1, Yujiro Yokoyama1, Toshio Oyama2, Taichiro Goto3.
Abstract
BACKGROUND: Although mediastinal lymph node cancer is presumed to originate in the lung, the primary site is usually unidentified, so the pathological course remains unclear. We recently encountered a case of mediastinal lymph node cancer having a putative primary lesion remaining in the lung as a necrotic focus. CASEEntities:
Keywords: Immunohistology; Lymph node cancer; Mediastinal cancer; Surgery; Unknown primary site
Mesh:
Year: 2018 PMID: 29606126 PMCID: PMC5880060 DOI: 10.1186/s12957-018-1373-y
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Fig. 1Computed tomography. A small nodule was found in the lingular segment
Fig. 2Positron emission tomography. a, b FDG uptake was detected in a subcarinal lymph node and not in a nodule in the lingular segment. The arrow indicates the lymph node with FDG accumulation
Fig. 3Histopathologic findings of the pulmonary nodule. a, b No viable cells could be observed inside the tumor (hematoxylin and eosin stain. a low magnification, b high magnification). c, d Vein filled with necrotic cells were observed (c hematoxylin and eosin stain; d Elastica van Gieson stain)
Fig. 4Immunohistochemical findings of the pulmonary nodule. Immunostaining results of the necrotic tissue were positive for pan-cytokeratin (AE1/AE3) and napsin A (a pan-cytokeratin immunostaining; b napsin A immunostaining)
Fig. 5Histopathologic findings of the subcarinal lymph node. a, b Solid proliferation of cancer cells was observed (hematoxylin and eosin stain. a low magnification, b high magnification). c, d Tumor cells were positive for pan-cytokeratin and napsin A (c pan-cytokeratin immunostaining; d napsin A)
Fig. 6Time-course changes in the serum CEA level. The abscissa denotes time, and 1 scale corresponds to 1 month. Parallel dotted lines indicate omission of an intermediate step
Cancers of the intrathoracic lymph nodes with unknown primary site
| Case | Author | Age (years) | Sex | Smoking history | Histology | Elevated TMs | Location | Treatment | Adjuvant treatment | Follow-up (months) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Morita Y | 56 | Male | + | SQ | None | Med | LB and LND | None | 20 | Alive without recurrence |
| 2 | Kohdono S | 67 | Male | + | LA | None | Med | Tumor resection | RTx | 6 | Died of recurrence |
| 3 | Kohdono S | 58 | Female | + | LA | CEA | Med | LB and LND | RTx | 6 | Alive with recurrence |
| 4 | Kohdono S | 56 | Male | + | Small | SCC | rt. Hilum | LB and LND | None | 16 | Alive without recurrence |
| 5 | Blanco N | 56 | Male | + | SQ | no data | Med | Tumor resection | CRT | No data | Alive without recurrence |
| 6 | Kawasaki H | 69 | Male | No data | LA | CEA | rt. Hilum | LB and LND | None | 20 | Alive without recurrence |
| 7 | Tomita M | 56 | Male | + | SQ | SCC | lt. Hilum | Tumor resection | None | 32 | Alive without recurrence |
| 8 | Miwa K | 72 | Male | + | SQ | CEA | Med | LND | RTx | 82 | Alive without recurrence |
| 9 | Miwa K | 78 | Male | + | AD | CEA | Med | LND | RTx | 44 | Alive without recurrence |
| 10 | Miwa K | 70 | Male | + | SQ | None | Med | CRT | N/A | 33 | Alive without disease progression |
| 11 | Miwa K | 76 | Male | + | Undifferentiated | CEA | Med | CRT | N/A | 24 | Alive without disease progression |
| 12 | Shiota Y | 69 | Male | + | AD | CEA | Med | CRT | N/A | 22 | Alive without disease progression |
| 13 | Harada H | 83 | Female | No data | AD | NSE | Med | Tumor resection | None | 38 | Alive without recurrence |
| 14 | Watanabe N | 55 | Female | – | AD | CEA | Med | ALK-TKI | N/A | 3 | Alive without disease progression |
| 15 | Kim M.J. | 59 | Male | + | SQ | None | rt. Hilum | PN and LND | CRT | No data | Alive without recurrence |
| 16 | Kawasaki H | 40 | Male | + | AD | CEA | Med | LB and LND | None | 126 | Alive with recurrence |
| 17 | Yamasaki M | 67 | Male | + | AD | CEA | Med | EGFR-TKI | N/A | 8 | Alive without disease progression |
| 18 | Present case | 56 | Male | + | AD | CEA | Med | LND | CRT | 32 | Alive without recurrence |
TM tumor marker, AD adenocarcinoma, SQ squamous cell carcinoma, LA large cell carcinoma, Undif undifferentiated carcinoma, SCC squamous cell carcinoma antigen, CEA carcinoembryonic antigen, NSE neuron-specific enolase, Med mediastinum, LB lobectomy, LND lymph node dissection, PN pneumonectomy, CRT chemoradiation therapy, ALK anaplastic lymphoma kinase, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, RTx radiation therapy